CVRx Funding Boost Will Sustain Barostim Heart Failure Device To US Launch

US heart failure device manufacturer CVRx has scored a double hit by securing $113 million in funding in this flat investor climate and by being one of the first into the US FDA’s EAP, designed to help innovative technologies get faster access to market. CVRx’s much larger rivals are doubtless watching events with an uneasy mix of interest and concern.

Privately-held CVRx Inc., developer of the Barostim Neo minimally invasive implantable system with separate indications for heart failure and resistant hypertension, has scored a major coup in securing $113 million in new funding in what remains a difficult market for medical device investment. The financing was led by Johnson & Johnson Development Corp., the venture arm of Johnson & Johnson.

Of equal significance, CVRx has also this year become one of the first beneficiaries of the US FDA’s Expedited Access...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Market Access

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-MarketAccess (Premium-1): Stimulant Medications Don’t Cause Psychosis, New Study Finds

 
• By 

Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD.

[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By 

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

 
• By 

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.